C2N Diagnostics
Focus: C2N Diagnostics is a St. Louis-based public company specializing in blood-based diagnostics and therapeutics for Alzheimer's disease and related neurodegenerative conditions. The company is positioned at the forefront of early Alzheimer's detection through its PrecivityAD platform.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About C2N Diagnostics
AI assessmentNot HiringNo open roles listed right now. Follow C2N Diagnostics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from C2N Diagnostics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Digital MoCA
Mild Cognitive ImpairmentClinical Trials (1)
NCT07041450Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers
N/AHelp build intelligence for C2N Diagnostics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.